François-Clément Bidard, Head of Center for Clinical Investigation, Inserm CIC-1428 at Inserm, shared a post on LinkedIn about a paper by Leandro Jonata Carvalho Oliveira et al. published in Breast Cancer Research and Treatment:
“PADA-1 / SERENA-6
A highly recommended read: a hands-on clinical perspective on how these ESR1-targeting approaches fit into clinical practice – within the broader landscape of liquid biopsies, including our previous strategic STIC trial (with CTC) and the ongoing ECLECTIC trial (with FES-PET and CTCs).
A big thank-you to our Brazilian colleagues for their sharp and well-argued analysis.”
Title: The promise of ctDNA-based, molecularly-driven early switch therapy from PADA-1 to SERENA-6
Authors: Leandro Jonata Carvalho Oliveira, Max Senna Mano, Carlos Barrio, Rodrigo Dienstmann
You can read the full article in Breast Cancer Research and Treatment.
More posts featuring François-Clément Bidard.
